Isabel Moreno

Isabel Moreno

España - Madrid


Isabel Moreno-indias is the co-Leader of the group Obesity, Diabetes and their comorbidities: prevention and treatment at IBIMA. With a background in Biology and Food Science, her research is focus on the study of metabolic diseases and particularly in their relationship with gut microbiota. After defended her thesis with honors in 2011, obtaining the Premio extraordinario de doctorado in Health Sciences at Universidad de las Palmas de Gran Canaria, she continued her research at Instituto de Investigaciones Biomédicas de Málaga, with different competitive contracts: Sara Borrell, Miguel Servet I and now Miguel Servet II from the ISCIII. She has developed several research stays during my career: at Oxford University, University of Pennsylvania or Copenhagen University. She has established her own research team based on understanding how gut microbiota works as a super-organ and how establish its relationships with the host. Particularly, She is especially interested in the implications of the gut microbiota in the reversion of obesity. She is focused on the study of dietary strategies for the amelioration of obesity, and the implication of the gut microbiome. Moreover, she is currently the head of the CIBER-IBIMA Metagenomics platform, which assists researchers over the country, as well as the scientific coordinator of the Genomics Platform at IBIMA. I actively maintain multiple national and international collaborations, especially with researchers from CIBERobn and SEEDO, as well as from two COST actions within I am the Spanish MC (CA18131 and CA20128). On the other hand, about her publications, She have maintaining an excellent trajectory during her whole career, with more than 80 SCI articles, an H index of 33 and more than 3600 cites. Moreover, She has presented her results in multiple national and international conferences, even as invited speaker. She is the co-inventor of four patents based on my investigations on gut microbiota. She has supervised two PhD thesis, plus other two on-going more. Moreover, She am referee in many SCI journals, editor in Frontiers in cellular and infectious microbiology and guess editor in Frontiers in Microbiology, grant reviewer: regionals, nationals (ANEP) and internationals (Czech Republic, Colombia, France, European Comission), and scientific advisor in international grants as well as national and international biotechnology companies.



-Biomedical Research Network in Physiopathology of Obesity and Nutrition (CIBEROBN)
-Carlos III Health Institute, Madrid, Spain
-Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, España


Diabetes and obesity: The role of the microbiota

Diabetes and obesity. The role of microbiota.

Gut microbiota has emerged as a new ‘virtual’ organ that is able to interact with the other organs and participate in the homeostasis of the host. Diet is one of the factors with the highest potential to modify the gut microbiota, in a good way or not. Occidental lifestyle has influenced in the burner of the high prevalence of non-communicable diseases, and especially in the increase of metabolic disease prevalence, particularly obesity and diabetes. For these chronic diseases, to follow a healthy lifestyle is imperative. In our group, we are studying how different lifestyle choices affect gut microbiota, and the implications of these changes in the metabolism of the host. Thus, we have studied different dietary choices: Mediterranean diet or ketogenic diet, or other kind of dietary choices, such as fasting. Moreover, we have been also interested in how fermented beverages can influence gut microbiota, and if the health boundaries relative to their consumption could be mediated, at least in part, by the gut microbiota.